肺功能检查联合心肺运动试验优化肥厚型心肌病分层
本研究为前瞻性两中心研究,纳入102例临床稳定的肥厚型心肌病患者,同期完成肺功能检查与心肺运动试验。患者肺功能保留(平均FVC 90.7%,FEV1 92.5%),FVC与FEV1均与峰值摄氧量及峰值通气量呈强相关,回归分析证实二者独立相关。提示肺功能检查可补充心肺运动试验,用于更全面评估运动能力与患者分层。
要点
- HCM患者肺功能多保留,但FVC、FEV1与CPET指标仍强相关
- FVC、FEV1与峰值VO₂相关系数分别为0.649与0.691
- 肺功能检查或可辅助CPET完善HCM患者分层
核心结论
- 在肥厚型心肌病患者中,肺功能指标与心肺运动试验参数强相关,肺功能检查可补充心肺运动试验以更全面评估运动能力和患者分层。
研究设计与样本
- 前瞻性两中心研究,纳入102例临床稳定的肥厚型心肌病患者,均接受肺功能检查与心肺运动试验。
- 采用Spearman相关与多重线性回归分析肺功能(FVC、FEV1)与CPET变量的关系,并校正混杂因素。
主要发现
- 患者肺功能保留,平均FVC为90.7%,FEV1为92.5%。
- FVC与峰值VO₂相关r=0.649(p<0.001),FEV1与峰值VO₂相关r=0.691(p<0.001)。
- FVC与峰值通气量相关r=0.682(p<0.001),FEV1与峰值通气量相关r=0.688(p<0.001)。
- 回归分析证实肺功能与CPET表现之间存在独立关联(均p<0.001)。
临床怎么用
- 对临床稳定的HCM患者,可在CPET基础上结合肺功能检查,更全面解读运动能力受限并辅助风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardiopulmonary exercise testing (CPET) is essential for assessing patients with hypertrophic cardiomyopathy (HCM), but the role of pulmonary function testing (PFT) in refining patient stratification remains underexplored. This study investigates the relationship between PFT and CPET parameters in patients with HCM. METHODS: In this prospective two-centre study, 102 clinically stable patients with HCM underwent PFT and CPET. Spearman's correlation and multiple linear regression were used to assess relationships between PFT (forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV₁)) and CPET variables, adjusting for confounders. RESULTS: Patients exhibited preserved lung function (mean FVC: 90.7%; FEV1: 92.5%). Strong correlations were observed between PFT and CPET metrics, including peak VO₂ (FVC: r=0.649, p<0.001; FEV₁: r=0.691, p<0.001) and peak ventilation (FVC: r=0.682, p<0.001; FEV₁: r=0.688, p<0.001). Regression analysis confirmed independent associations between PFT and CPET performance (all p<0.001). CONCLUSION: PFT metrics strongly correlate with CPET parameters in HCM, suggesting that PFT could complement CPET for a more comprehensive assessment of exercise capacity and patient stratification.
引用
- Willixhofer R, Mapelli M, Baracchini N, et al. Integrating pulmonary function testing with cardiopulmonary exercise testing for enhanced stratification in hypertrophic cardiomyopathy. Heart. 2025. PMID: 40240134. doi:10.1136/heartjnl-2025-325737
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。